Scientists watch EBV wake up in healthy young people

NCT ID NCT07536048

Ongoing Knowledge-focused Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 100 healthy adults aged 18 to 29 who have had Epstein-Barr virus (EBV) in the past. Researchers collect blood and saliva samples over 6 to 12 months to see when the virus becomes active again and how the immune system responds. No treatments or vaccines are given—the goal is simply to gather information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help researchers understand why EBV reactivates and how the immune system responds, potentially guiding future treatments or vaccines.
What could go wrong: This is an observational study with no intervention, so it won't directly test any treatment. It is small (100 participants) and only follows people for up to a year, which may limit how much we learn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS (EBV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPSTEIN-BARR VIRUS (EBV) HEALTHY VOLUNTEERS

Contacts and locations

Locations

Griffith - University Clinical Trial Unit - Site Number : 0360001

Gold Coast, 4222, Australia
University of Sunshine Coast - Site Number : 0360002

South Brisbane, 4101, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.